Hemorrhage in Early Pregnancy and Antepartum Hemorrhage: Contemporary Diagnosis, Management and Maternal–Fetal Outcomes

1. Chauhan Ayushi

2. Osmonova Gulnaz Zhenishbaevna

(1. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic

2. Teacher, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.)

Abstract

Hemorrhage during pregnancy remains one of the most clinically significant presentations in obstetric practice because the underlying causes range from benign, self-limiting conditions to rapidly fatal maternal or fetal emergencies. Vaginal bleeding in early pregnancy is common and may occur in a viable intrauterine pregnancy, threatened miscarriage, early pregnancy loss, ectopic pregnancy, pregnancy of unknown location, cervical or vaginal pathology, or, less frequently, gestational trophoblastic disease. In later pregnancy, antepartum haemorrhage (APH) represents a distinct obstetric syndrome and is traditionally defined as bleeding from or into the genital tract from 24+0 weeks of gestation until delivery. Placental abruption and placenta praevia are the principal serious causes, while vasa praevia, uterine rupture, cervical lesions, labour-related bleeding and other genital tract abnormalities must also be considered. APH complicates approximately 3–5% of pregnancies and remains an important contributor to maternal and perinatal morbidity and mortality.

This narrative review examines the epidemiology, pathophysiology, clinical presentation, diagnostic approach, treatment and outcomes associated with hemorrhage in early pregnancy and APH. Particular attention is given to contemporary ultrasound-based diagnosis, the appropriate interpretation of serum β-human chorionic gonadotropin, recognition and management of ectopic pregnancy, evidence-based treatment of miscarriage, the diagnostic limitations of ultrasound in placental abruption, the management of placenta praevia and placenta accreta spectrum, and the emergency management of vasa praevia. Current international recommendations increasingly emphasize early risk recognition, maternal stabilization, multidisciplinary preparation, appropriate use of blood products, individualized timing of delivery and avoidance of unnecessary intervention in pregnancies that may remain viable. Recent evidence also demonstrates that the consequences of APH extend beyond the immediate bleeding episode, with substantial associations with preterm birth, neonatal intensive care admission, stillbirth and postpartum hemorrhage. Contemporary obstetric care therefore requires not only accurate identification of the source of bleeding but also coordinated anticipation of subsequent maternal and neonatal complications.

Keywords: early pregnancy bleeding; antepartum haemorrhage; miscarriage; ectopic pregnancy; placental abruption; placenta praevia; placenta accreta spectrum; vasa praevia; obstetric hemorrhage; maternal morbidity; perinatal outcome.

1. Introduction

Bleeding during pregnancy is one of the most challenging presentations encountered by clinicians because the same outward symptom—blood loss from the genital tract—can represent fundamentally different pathological processes depending on gestational age, hemodynamic status, pain characteristics, fetal status and placental anatomy. A small amount of vaginal bleeding in an otherwise stable woman with a confirmed intrauterine pregnancy may ultimately have no adverse consequence, whereas apparently modest bleeding in a woman with an ectopic pregnancy or concealed placental abruption can precede rapid cardiovascular collapse. The clinical significance of pregnancy-associated bleeding therefore cannot be judged from the volume of visible blood alone. A structured approach must integrate the maternal condition, pregnancy location and viability, gestational age, placental position, fetal condition and the possibility of concealed hemorrhage.

The terminology surrounding obstetric bleeding is itself important. “Early pregnancy bleeding” usually refers to vaginal bleeding during the first trimester and, in clinical practice, often encompasses bleeding before a definitive diagnosis of pregnancy viability or location has been established. By contrast, antepartum haemorrhage is a specific obstetric term. The Royal College of Obstetricians and Gynaecologists (RCOG) defines APH as bleeding from or into the genital tract from 24+0 weeks of pregnancy and before the birth of the baby. According to RCOG, APH complicates approximately 3–5% of pregnancies and remains an important cause of maternal and perinatal mortality.

This distinction is not merely semantic. The differential diagnosis, investigations and therapeutic priorities change markedly as pregnancy progresses. In early pregnancy, the central diagnostic challenge is to determine whether a pregnancy is intrauterine or ectopic and whether an intrauterine pregnancy is viable. Transvaginal ultrasonography and serial serum β-human chorionic gonadotropin measurements are central to this assessment. Contemporary guidance emphasizes that premature diagnosis of pregnancy loss must be avoided because treatment based on an incorrect diagnosis can interrupt a potentially viable pregnancy. The 2025 Canadian guideline on intrauterine early pregnancy loss similarly emphasizes that incorrect diagnosis can harm a normally sited viable pregnancy, while excessive delays in diagnosis may increase psychological distress and postpone necessary treatment.

In later pregnancy, the diagnostic priorities are different. The clinician must rapidly distinguish placenta praevia, placental abruption, vasa praevia, uterine rupture and other causes of genital tract bleeding. Placental abruption is characterized by premature separation of the placenta from the uterine decidua and may present with vaginal bleeding, abdominal pain, uterine contractions or fetal heart-rate abnormalities. Importantly, visible vaginal bleeding may underestimate the true extent of hemorrhage because blood can remain trapped behind the placenta. A contemporary review estimates placental abruption to occur in approximately 0.4–1.0% of pregnancies and emphasizes that ultrasound may have limited sensitivity for the diagnosis.

Placenta praevia presents a different clinical pattern. It occurs when the placenta lies over or very close to the internal cervical os and classically causes painless vaginal bleeding, particularly in the third trimester. Its clinical significance extends beyond antepartum bleeding because placenta praevia is strongly associated with placenta accreta spectrum (PAS), especially in women with previous caesarean delivery. Current RCOG guidance notes that the rates of both placenta praevia and PAS have increased and are likely to continue increasing in association with rising caesarean delivery rates and assisted reproductive technology.

The consequences of pregnancy-related hemorrhage are not confined to immediate blood loss. Severe bleeding may produce hypovolemic shock, anemia, disseminated intravascular coagulation, renal injury, emergency surgery and maternal death. For the fetus, hemorrhage may lead to hypoxia, prematurity, growth restriction, stillbirth and neonatal death. Even when the pregnancy survives, hemorrhage may be associated with subsequent developmental and neurological morbidity, particularly when it results in extreme prematurity. RCOG has highlighted the association between APH and very preterm birth, noting that up to one-fifth of very preterm infants may be born in association with APH.

The contemporary approach to obstetric hemorrhage has consequently shifted from a purely diagnostic model toward an integrated model of prediction, rapid stabilization, multidisciplinary preparedness and individualized delivery planning. Advances in ultrasonography have improved recognition of placental abnormalities and ectopic pregnancy. Improvements in blood-component therapy, massive transfusion protocols, obstetric anesthesia, interventional radiology and neonatal intensive care have further changed outcomes. Nevertheless, the effectiveness of these advances depends heavily on timely recognition and coordinated action.

The objective of this review is to synthesize current evidence regarding hemorrhage in early pregnancy and APH, with emphasis on etiology, pathophysiology, clinical manifestations, diagnosis, management and maternal–fetal outcomes. The review also considers areas in which contemporary recommendations have evolved, including progesterone therapy for selected patients with threatened miscarriage, conservative and medical treatment of ectopic pregnancy, the increasing importance of prenatal diagnosis of PAS and vasa praevia, and the need to individualize delivery decisions in APH.

2. Methods

This article was developed as a narrative evidence-based review using contemporary international guidelines, professional society recommendations, peer-reviewed reviews, cohort studies and relevant clinical evidence. Literature and guidance were reviewed from major professional and governmental sources, including the National Institute for Health and Care Excellence (NICE), the American College of Obstetricians and Gynecologists (ACOG), the Royal College of Obstetricians and Gynaecologists (RCOG), the World Health Organization (WHO), the American College of Radiology and PubMed-indexed medical literature.

Particular attention was given to guidance and studies published or updated between 2024 and 2026, while established guidelines and landmark recommendations were retained where they continue to inform contemporary practice. The current NICE guideline on ectopic pregnancy and miscarriage was updated in June 2026 and was therefore used as an important source for early pregnancy assessment, ultrasound diagnosis, pregnancy of unknown location, ectopic pregnancy and miscarriage management.

The review was structured around the clinical pathway from initial presentation to definitive management. For early pregnancy bleeding, the literature was synthesized according to pregnancy location, viability and hemodynamic status. For APH, the evidence was organized around placental causes, maternal stabilization, fetal assessment, diagnostic imaging and timing and mode of delivery. Recent reviews of placental abruption, placenta praevia and first-trimester vaginal bleeding were specifically incorporated to ensure that developments in diagnostic imaging and contemporary obstetric management were represented.

Because this is a narrative review rather than an original clinical investigation, no patient-level data were collected and no institutional ethical approval was required. The purpose of the methodological approach was to synthesize clinically relevant evidence rather than perform a formal systematic review or meta-analysis.

3. Results

3.1 Hemorrhage in Early Pregnancy

Early pregnancy bleeding is common and is one of the principal reasons for presentation to emergency departments and early pregnancy assessment services. The differential diagnosis ranges from normal or potentially viable pregnancies to miscarriage, ectopic pregnancy and gestational trophoblastic disease. A recent American College of Radiology review emphasizes that the major diagnostic possibilities in first-trimester bleeding include a normal intrauterine pregnancy, nonviable intrauterine pregnancy, ectopic pregnancy and, less commonly, gestational trophoblastic disease. Most cases can be evaluated using a combination of clinical assessment, ultrasound and serum β-hCG measurements.

The initial assessment should begin with the same principle used in every obstetric hemorrhage: determine whether the patient is clinically stable. Tachycardia, hypotension, syncope, pallor, altered mental status, severe abdominal pain or evidence of peritoneal irritation should immediately raise concern for significant internal hemorrhage, particularly ruptured ectopic pregnancy. The amount of blood reported by the patient should not be interpreted in isolation because external vaginal bleeding does not reliably reflect the amount of intra-abdominal bleeding.

Once immediate instability has been addressed, a focused history should establish the gestational age, date of the last menstrual period, pregnancy test history, quantity and duration of bleeding, presence of clots or tissue, abdominal or pelvic pain, shoulder-tip pain, dizziness or syncope, previous ectopic pregnancy, previous miscarriage, fertility treatment, intrauterine contraception, pelvic infection, previous tubal surgery and previous caesarean or uterine surgery. Previous pregnancy history is particularly important because previous ectopic pregnancy increases the likelihood of another ectopic pregnancy, while previous miscarriage is relevant to the management of threatened miscarriage.

Physical examination should include assessment of vital signs, abdominal tenderness, guarding and rebound tenderness, as well as evaluation for signs of shock. Pelvic examination may be indicated depending on the clinical circumstances, although transvaginal ultrasound is generally the principal imaging investigation. Cervical bleeding, visible products of conception and local cervical lesions may provide useful diagnostic information.

3.1.1 Threatened Miscarriage

Threatened miscarriage is characterized by vaginal bleeding in a pregnancy that remains potentially viable, usually with a closed cervical os and no evidence that pregnancy tissue has been expelled. Vaginal bleeding and mild uterine cramping can occur in otherwise normal pregnancies, which is why the presence of bleeding should not automatically be equated with pregnancy loss.

The prognosis depends on gestational age, bleeding severity, ultrasound findings and previous obstetric history. A confirmed intrauterine pregnancy with fetal cardiac activity is reassuring, although it does not completely eliminate the risk of subsequent miscarriage. The current NICE guideline recommends vaginal micronized progesterone at a dose of 400 mg twice daily for women with a confirmed intrauterine pregnancy who present with vaginal bleeding and have previously experienced a miscarriage. If a fetal heartbeat is confirmed, progesterone is continued until 16 completed weeks. NICE does not recommend progesterone routinely for women with early pregnancy bleeding who have no previous miscarriage.

The distinction is clinically important because progesterone therapy is not a universal treatment for all first-trimester bleeding. Evidence indicates benefit in the subgroup combining current early pregnancy bleeding with a history of miscarriage. Applying the treatment indiscriminately to all women with bleeding may expose patients to medication without demonstrated benefit while diverting attention from the need to exclude ectopic pregnancy or nonviable gestation.

Patients with threatened miscarriage require appropriate safety-netting. Increasing bleeding, persistent bleeding, worsening pain, dizziness, syncope or systemic symptoms should prompt reassessment. Emotional support is equally important. Even when the pregnancy remains viable, bleeding can generate considerable anxiety, and clinicians should avoid language that implies the patient has caused or failed to prevent the bleeding.

3.1.2 Early Pregnancy Loss and Miscarriage

Early pregnancy loss is one of the most common complications of pregnancy. ACOG defines early pregnancy loss as a nonviable intrauterine pregnancy within the first trimester and reports that approximately 10% of clinically recognized pregnancies end in early pregnancy loss, with the majority occurring during the first trimester. Approximately half of early pregnancy losses are associated with fetal chromosomal abnormalities.

The diagnosis should be established with appropriate certainty before treatment is initiated. This is particularly important at very early gestational ages when a pregnancy may simply be too early to demonstrate expected ultrasound findings. Current NICE guidance recommends transvaginal ultrasound to establish pregnancy location and assess viability. When an embryo is visible but no heartbeat is detected, crown–rump length should be measured. When the crown–rump length is below 7 mm and there is no visible heartbeat, NICE recommends repeat scanning after at least seven days before a definitive diagnosis is made. Even when the crown–rump length is 7 mm or greater without visible cardiac activity, a second opinion and/or repeat scan is recommended before diagnosing miscarriage.

The conservative approach to ultrasound diagnosis reflects an important ethical principle: a false-positive diagnosis of miscarriage is irreversible, whereas a repeat scan is reversible and usually safe. The 2025 Canadian guideline similarly emphasizes the balance between avoiding incorrect interruption of a viable pregnancy and avoiding unnecessary delay in diagnosis.

Once miscarriage has been confirmed, management may be expectant, medical or surgical. Expectant management allows spontaneous passage of pregnancy tissue and is appropriate for many clinically stable patients. NICE recommends expectant management for seven to fourteen days as a first-line option in appropriate patients, while also recognizing that other strategies may be preferable when the woman has an increased risk from hemorrhage, infection or other clinical circumstances.

Medical treatment has become increasingly important. Current NICE guidance recommends 200 mg of oral mifepristone followed 48 hours later by 800 micrograms of misoprostol for missed miscarriage, while 600 micrograms of misoprostol is recommended for incomplete miscarriage, with 800 micrograms an alternative in some protocols. Pain relief and antiemetics should be provided according to clinical need.

Surgical treatment remains appropriate when there is heavy bleeding, hemodynamic instability, infection, retained tissue with significant symptoms, contraindication to medical or expectant management, or a patient preference for rapid resolution. Manual vacuum aspiration under local anesthesia may be appropriate in suitable settings, while theatre-based surgical evacuation remains an alternative. NICE specifically recognizes both approaches as appropriate choices when clinically indicated.

The management of miscarriage should also address psychological consequences. Pregnancy loss is not merely a physiological event; it may involve grief, guilt, anxiety and uncertainty regarding future pregnancies. Patient-centered care requires that the woman be informed of available options and allowed to participate meaningfully in the decision. Contemporary guidelines increasingly recognize the importance of individualized care, rather than assuming that a single management strategy is appropriate for every patient.

3.1.3 Ectopic Pregnancy

Ectopic pregnancy represents the most important potentially life-threatening cause of early pregnancy bleeding. The majority occur within the fallopian tube, although implantation may occur in cervical, interstitial, caesarean-scar, ovarian, abdominal or other locations. The classical presentation consists of amenorrhea, abdominal or pelvic pain and vaginal bleeding, but clinical presentations vary considerably. A 2024 emergency medicine review emphasizes that many women with ectopic pregnancy have no identifiable classical risk factor, meaning that clinicians cannot safely exclude ectopic pregnancy solely because the patient lacks a recognized predisposition.

Transvaginal ultrasound is the principal imaging modality. NICE recommends ultrasound to establish pregnancy location and viability. Definite sonographic evidence of a tubal ectopic pregnancy includes an adnexal gestational sac containing a yolk sac or fetal pole, particularly when it moves separately from the ovary. Other findings, including an empty uterus, complex adnexal mass or free fluid, increase suspicion but are not independently diagnostic. Moderate or large-volume intraperitoneal fluid may represent hemoperitoneum and should be interpreted in the context of the clinical picture.

Pregnancy of unknown location represents an important intermediate diagnostic state. It should not be treated as an ectopic pregnancy simply because no intrauterine gestational sac is visualized. Serial serum β-hCG measurements, typically approximately 48 hours apart, may assist in determining the trajectory of the pregnancy, but β-hCG alone cannot establish pregnancy location. NICE emphasizes that serum hCG should be used primarily to assess trophoblastic proliferation and guide subsequent management rather than as a standalone diagnostic test for ectopic pregnancy.

Management depends on clinical stability, symptoms, ultrasound findings, β-hCG concentration, ability to comply with follow-up and patient preference. Expectant management is an option for carefully selected stable patients with small, unruptured tubal ectopic pregnancies and low or appropriately declining hCG concentrations. NICE recommends expectant management for patients who are clinically stable and pain-free, with a tubal ectopic pregnancy less than 35 mm, no visible fetal heartbeat, and hCG ≤1,000 IU/L, provided reliable follow-up is possible. It may also be considered when hCG is between 1,000 and 1,500 IU/L.

Methotrexate is an important non-surgical treatment for selected patients. Current NICE recommendations support systemic methotrexate in women with an unruptured tubal ectopic pregnancy, no significant pain, an adnexal mass smaller than 35 mm, no visible fetal heartbeat, hCG below 1,500 IU/L and no intrauterine pregnancy, provided follow-up is feasible. Surgery is recommended as first-line treatment when there is significant pain, an adnexal mass ≥35 mm, visible fetal cardiac activity, hCG ≥5,000 IU/L or inability to participate in follow-up. Between 1,500 and 5,000 IU/L, either methotrexate or surgery may be offered to appropriately selected patients.

Ruptured ectopic pregnancy is an emergency requiring immediate resuscitation and operative management. Intravenous access, blood sampling, crossmatching and rapid communication with the surgical and anesthesia teams should occur simultaneously with stabilization. The priority is not to achieve a perfect preoperative diagnosis but to prevent exsanguination.

3.1.4 Other Causes of Early Pregnancy Bleeding

Although miscarriage and ectopic pregnancy account for most clinically important causes, other conditions must remain in the differential diagnosis. Implantation-related bleeding is often invoked by patients and clinicians, although it should not be used as a diagnosis of exclusion when significant bleeding or pain is present. Cervical ectropion, cervicitis, cervical polyps and sexually transmitted infections may cause bleeding, especially after intercourse or pelvic examination.

Subchorionic hematoma is another recognized cause of first-trimester bleeding. Its prognostic significance depends on size, location, gestational age and associated findings. Most cases do not require invasive treatment, although appropriate follow-up may be indicated.

Gestational trophoblastic disease is uncommon but clinically important. A markedly elevated β-hCG, uterine size greater than expected for gestational age, hyperemesis or characteristic ultrasound findings should prompt consideration of a molar pregnancy. Because management and follow-up differ fundamentally from miscarriage, accurate diagnosis is essential.

Rh(D) alloimmunization also requires consideration in bleeding during pregnancy. Recommendations have changed in recent years, and practice differs between jurisdictions. ACOG's 2025 Clinical Practice Update specifically revisited Rh(D) immune globulin administration after abortion or pregnancy loss at less than 12 weeks. Therefore, institutions should follow their current national or local protocol rather than applying older universal rules without qualification. ACOG continues to recognize Rh(D) prophylaxis as an important component of prevention of alloimmunization in indicated circumstances.

3.2 Antepartum Haemorrhage

Antepartum haemorrhage is traditionally defined as genital tract bleeding from 24+0 weeks of gestation until delivery. RCOG estimates that APH complicates 3–5% of pregnancies and identifies placenta praevia and placental abruption as the most important causes, although they are not the most frequent overall causes of bleeding.

The clinical approach to APH begins with simultaneous assessment of maternal and fetal well-being. Maternal stabilization must never be delayed while attempting to establish the precise cause of bleeding. Two large-bore intravenous cannulas should generally be established in significant hemorrhage, blood should be taken for complete blood count, blood group and crossmatch and coagulation testing, and the blood bank should be alerted early when substantial bleeding is suspected. The extent of resuscitation depends on clinical condition rather than an isolated hemoglobin concentration because acute blood loss may initially occur before hemoglobin falls substantially.

The fetus should be assessed promptly once maternal stabilization has begun. Continuous cardiotocographic monitoring is usually appropriate when the fetus is viable and the maternal condition permits. Fetal heart-rate abnormalities may be an early indication of placental insufficiency, abruption or fetal hemorrhage in vasa praevia.

A critical principle in the physical examination is that digital vaginal examination should be avoided until placenta praevia has been excluded. Digital examination in the presence of a placenta covering the cervical os may provoke catastrophic hemorrhage. Ultrasound should therefore be used to establish placental location before a digital examination is performed.

3.2.1 Placental Abruption

Placental abruption is defined as premature separation of the placenta from the uterine wall before delivery. It is one of the most important causes of APH and can result in severe maternal hemorrhage, fetal compromise, preterm birth and fetal death.

The underlying pathophysiology is complex and is not completely understood. Decidual vascular injury, placental ischemia, inflammation, abnormal trophoblastic invasion and maternal vascular disease may contribute to placental separation. Risk factors include hypertensive disorders of pregnancy, previous abruption, smoking, cocaine use, trauma, premature rupture of membranes, thrombophilic or vascular conditions and other placental disorders. A recent systematic review identified previous placental abruption as one of the strongest independent risk factors for recurrence and also found significant associations with hypertensive disease, placenta praevia, preterm membrane rupture and fetal growth abnormalities.

The classic presentation consists of painful vaginal bleeding, abdominal or back pain, uterine tenderness and frequent uterine contractions. However, the presentation is variable. Bleeding may be concealed behind the placenta, producing severe maternal or fetal compromise despite minimal visible vaginal bleeding. In severe cases, the uterus may become tense and tender, and disseminated intravascular coagulation may develop as a result of the release of tissue factor from the damaged placenta and decidua.

The diagnosis of placental abruption remains predominantly clinical. Ultrasound can identify alternative diagnoses such as placenta praevia and may occasionally demonstrate a retroplacental hematoma, but a normal ultrasound does not exclude abruption. The 2025 review by Schneider and Kinzler specifically emphasizes the limitations of ultrasound and recommends management based on gestational age, fetal status and maternal hemodynamic stability rather than imaging alone.

Laboratory evaluation should include complete blood count, coagulation studies, fibrinogen and blood group and crossmatch in significant cases. Hypofibrinogenemia may indicate severe consumptive coagulopathy and should be interpreted as part of the overall clinical picture.

Management depends primarily on maternal stability, fetal status and gestational age. Maternal instability or persistent severe bleeding generally necessitates urgent delivery regardless of gestational age when continuation of pregnancy threatens maternal life. If the fetus is alive and there is significant fetal compromise, emergency caesarean delivery is generally indicated when vaginal birth is not imminent. If fetal death has occurred and the mother is stable, vaginal delivery is usually preferred because caesarean delivery exposes the mother to additional surgical morbidity without fetal benefit.

In stable patients with preterm gestation, conservative management may sometimes be considered under close maternal and fetal surveillance. The decision requires access to an appropriate obstetric and neonatal facility and careful assessment of recurrence of bleeding, fetal growth, fetal well-being and preterm labor. Corticosteroids should be considered or administered when preterm delivery is anticipated according to gestational age and local guidelines. NICE currently recommends maternal corticosteroids for suspected or established preterm birth between 24+0 and 33+6 weeks and consideration between 34+0 and 35+6 weeks.

When birth is likely at very preterm gestations, magnesium sulfate for fetal neuroprotection should also be considered according to gestational age and institutional protocol. NICE recommends magnesium sulfate for established preterm labor or planned preterm birth at 24+0–29+6 weeks and consideration at 30+0–33+6 weeks.

3.2.2 Placenta Praevia

Placenta praevia is an important cause of APH and classically presents with painless, bright-red vaginal bleeding. The bleeding can be recurrent and unpredictable. Placental location is routinely assessed by ultrasound, and transvaginal ultrasound is safe and more accurate than transabdominal imaging for defining the relationship between the placenta and internal cervical os.

The increasing frequency of caesarean delivery has contributed to the growing clinical importance of placenta praevia and placenta accreta spectrum. RCOG reports that rates of both conditions have increased, with assisted reproductive technology, particularly in vitro fertilization, also contributing to risk.

Antenatal recognition of placenta praevia is essential because management can be planned before catastrophic bleeding occurs. Women with placenta praevia and previous caesarean delivery require particular attention to the possibility of PAS. ACOG notes that the risk of PAS rises dramatically when placenta praevia coexists with previous caesarean delivery. In its guidance, ACOG reports PAS risks of approximately 3%, 11%, 40%, 61% and 67% associated with placenta praevia after the first, second, third, fourth and fifth or subsequent caesarean deliveries, respectively.

The diagnosis of PAS is primarily based on expert ultrasound assessment. Features may be recognized as early as the first trimester, although most cases are identified during the second or third trimester. Antenatal diagnosis is highly desirable because maternal outcomes improve when delivery occurs in an appropriately equipped high-level center before labor or major bleeding and when attempts are made to avoid disruption of the placenta.

Women with recurrent bleeding from placenta praevia require individualized decisions regarding hospitalization, proximity to an obstetric center, corticosteroid administration and timing of delivery. The decision cannot be based solely on gestational age because recurrent hemorrhage, anemia, previous bleeding episodes, cervical changes, fetal status and access to emergency care all influence risk.

When delivery is indicated because of placenta praevia, caesarean delivery is generally required because the placenta obstructs the normal vaginal route. If PAS is suspected, delivery should be planned in a multidisciplinary center with expertise in major obstetric hemorrhage and access to blood products, anesthesia, neonatal care and surgical specialists.

3.2.3 Placenta Accreta Spectrum

Placenta accreta spectrum encompasses abnormally adherent and invasive placentation, ranging from abnormal attachment to deep invasion through the myometrium and, in severe cases, adjacent organs. The condition is clinically important because attempted removal of an invasive placenta can produce catastrophic hemorrhage.

The most important risk combination is placenta praevia with previous caesarean delivery. The pathophysiological basis is thought to involve disruption of the normal endometrial–myometrial interface at the site of a uterine scar, allowing abnormal placental implantation and invasion.

Antenatal diagnosis has therefore become a central component of prevention. Women identified as high risk should undergo targeted ultrasound assessment by clinicians experienced in placental imaging. MRI can have a complementary role in selected cases, particularly when ultrasound findings are uncertain or when the extent of invasion needs additional anatomical clarification.

Management requires detailed antenatal planning. ACOG recommends delivery at a level III or IV maternal care facility when PAS is suspected because outcomes are optimized when the diagnosis is known before delivery and the delivery is performed by an experienced multidisciplinary team.

The traditional management of confirmed PAS has been planned caesarean hysterectomy with the placenta left in situ. Attempting manual removal of an invasive placenta is generally avoided because it can trigger uncontrollable hemorrhage. Conservative approaches have been investigated in selected circumstances, particularly when fertility preservation is strongly desired, but these approaches require careful patient selection and extensive counseling regarding delayed hemorrhage, infection, retained placental tissue and the possibility of secondary hysterectomy.

The management of PAS illustrates a broader transformation in obstetric hemorrhage care: prevention through antenatal diagnosis may be more effective than attempting to control hemorrhage after it has already begun.

3.2.4 Vasa Praevia

Vasa praevia occurs when unprotected fetal blood vessels traverse the membranes over or near the internal cervical os. These vessels are vulnerable to rupture when the membranes rupture, either spontaneously or following amniotomy. Because fetal blood volume is relatively small, fetal exsanguination can occur extremely rapidly.

The RCOG guideline identifies two principal types: type I, associated with velamentous cord insertion, and type II, associated with a succenturiate or bilobed placenta. Vasa praevia may be suspected antenatally using ultrasound with color Doppler.

The classic emergency presentation is vaginal bleeding following rupture of membranes accompanied by sudden fetal bradycardia or other severe fetal compromise. The maternal condition may remain relatively stable because the bleeding is fetal rather than maternal. This distinction is critical: an apparently well mother with vaginal bleeding and sudden fetal deterioration should immediately raise suspicion for vasa praevia.

RCOG notes that fetal mortality in undiagnosed rupture can be extremely high, whereas antenatal diagnosis followed by planned caesarean delivery can result in survival exceeding 95% in reported series.

A 2026 RCOG peer-review draft of the updated vasa praevia guideline proposes planned caesarean birth at approximately 35+0 to 36+6 weeks for asymptomatic low-risk women with confirmed vasa praevia, while emphasizing individualized decisions regarding antenatal hospitalization. It also stresses that when rupture is suspected and fetal compromise is present, delivery should not be delayed while attempting to establish the diagnosis.

3.2.5 Less Common Causes of Antepartum Haemorrhage

Although placenta praevia and placental abruption dominate the differential diagnosis of serious APH, clinicians must also consider cervical and vaginal pathology, genital tract trauma, infections, polyps, cervical carcinoma, bloody show associated with labor, uterine rupture and fetal vessel abnormalities.

Uterine rupture is particularly important in women with a previous uterine scar, especially during labor. It may present with abdominal pain, abnormal fetal heart rate, cessation of contractions, maternal instability or vaginal bleeding. The absence of vaginal bleeding does not exclude rupture because hemorrhage may occur primarily into the peritoneal cavity.

Trauma can produce placental abruption even when the apparent external injury is limited. Assessment following significant abdominal trauma should therefore consider fetal and placental complications rather than focusing exclusively on maternal physical injury.

Cervical cancer is an uncommon cause of APH but should be considered when bleeding is persistent, recurrent or associated with an abnormal cervical appearance. A pregnancy does not protect against malignancy, and suspicious cervical findings should not be dismissed as pregnancy-related changes.

3.3 Diagnostic Principles Across Gestational Age

Despite major differences in etiology, several principles apply to both early pregnancy bleeding and APH. The first is that maternal stabilization precedes definitive etiological diagnosis in an unstable patient. The second is that visible vaginal blood loss is an imperfect measure of total blood loss. The third is that diagnostic testing must be interpreted within the clinical context rather than in isolation.

Ultrasound has become central to modern obstetric hemorrhage assessment. In early pregnancy, transvaginal ultrasound is used to establish pregnancy location and viability. In later pregnancy, ultrasound identifies placental location, evaluates fetal condition and may provide evidence regarding placental abnormalities. However, ultrasound is not equally sensitive for every diagnosis. A normal ultrasound cannot reliably exclude placental abruption, whereas transvaginal ultrasound is highly valuable for defining placenta praevia.

The 2025 American College of Radiology criteria for first-trimester bleeding emphasize the importance of combining ultrasound, serum hCG and clinical assessment while avoiding treatment of a potentially normal pregnancy based on incomplete evidence.

Laboratory evaluation should be proportionate to severity. In significant bleeding, hemoglobin and platelet count provide information about anemia and thrombocytopenia, while coagulation studies and fibrinogen are important when placental abruption or major hemorrhage is suspected. Blood group and crossmatching should occur early when substantial bleeding is possible.

Point-of-care assessment of hemodynamics may assist resuscitation. However, clinicians should recognize that pregnancy produces physiological changes in blood volume and cardiovascular parameters that can mask early shock. A pregnant patient can lose a significant amount of blood before hypotension becomes obvious. Tachycardia, altered mental status, reduced urine output, cool extremities and deteriorating fetal status may therefore be clinically important warning signs.

3.4 Resuscitation and Hemorrhage Control

The treatment of major obstetric hemorrhage is fundamentally multidisciplinary. Obstetricians, anesthesiologists, midwives, nurses, hematology or transfusion specialists, laboratory staff and neonatologists may all be required depending on severity and gestational age.

Initial resuscitation includes airway and breathing assessment, oxygen administration when clinically indicated, large-bore intravenous access, blood sampling and rapid communication with the blood bank. Crystalloid solutions may be used initially, but excessive crystalloid administration should be avoided when substantial blood loss is suspected because dilutional coagulopathy can develop.

Blood-component therapy should be guided by clinical hemorrhage and laboratory findings. Red-cell transfusion restores oxygen-carrying capacity, while plasma and platelet replacement address coagulation deficits. Fibrinogen is particularly important in major obstetric hemorrhage because pregnancy is physiologically hypercoagulable and fibrinogen concentration is normally elevated; a falling fibrinogen concentration in the setting of active hemorrhage may therefore indicate significant consumptive coagulopathy.

Massive transfusion protocols should be established at institutional level rather than improvised during a crisis. The exact ratio and sequence of blood components differ between protocols and clinical circumstances. The essential principle is early recognition and simultaneous correction of hypovolemia, anemia, coagulopathy, hypothermia and metabolic abnormalities.

Recent international guidance on obstetric hemorrhage has increasingly emphasized standardized, early recognition and coordinated treatment rather than waiting for conventional numeric thresholds before activating a response. WHO's consolidated 2025 recommendations address prevention, diagnosis and treatment of postpartum hemorrhage across antenatal, intrapartum and immediate postpartum care and highlight the importance of evidence-based systems capable of rapid response to severe bleeding. Although postpartum hemorrhage is distinct from APH, the same infrastructure—rapid blood access, trained teams and standardized hemorrhage protocols—is critical to managing severe antepartum bleeding.

Tranexamic acid deserves careful consideration in this context. Its established role is strongest in postpartum hemorrhage and trauma-related bleeding rather than as routine therapy for every episode of APH. Newer evidence is evaluating its role around delivery in high-risk placental disorders. A 2026 randomized phase 3 trial involving women with placenta praevia undergoing caesarean delivery found that prophylactic tranexamic acid produced a modest reduction in postpartum hemorrhage, although the intervention was administered after cord clamping and therefore should not be interpreted as evidence for routine treatment of antepartum bleeding itself.

3.5 Maternal and Perinatal Outcomes

The consequences of pregnancy-related hemorrhage extend beyond the immediate bleeding episode. Maternal complications include anemia, transfusion, hypovolemic shock, disseminated intravascular coagulation, emergency hysterectomy, renal injury, intensive care admission and death. Psychological consequences may also be considerable, especially following miscarriage, ectopic pregnancy or traumatic emergency delivery.

For the fetus and neonate, the consequences are strongly influenced by gestational age and the underlying cause of hemorrhage. Placental abruption can result in acute fetal hypoxia and stillbirth, whereas placenta praevia more commonly contributes to preterm birth through recurrent bleeding and planned or emergency delivery. Vasa praevia is distinctive because the fetus can experience profound acute blood loss in a very short time.

A 2025 retrospective cohort study from Northern Ethiopia demonstrated the broad association between APH and adverse outcomes. Women with APH had substantially higher risks of postpartum hemorrhage, emergency caesarean delivery and preterm birth, while their infants had higher risks of low birth weight, stillbirth, perinatal death, low Apgar scores and neonatal intensive care admission.

The association between APH and prematurity is particularly important because prematurity may mediate some of the observed neurological and developmental consequences traditionally attributed directly to antepartum bleeding. RCOG similarly notes that the relationship between APH and cerebral palsy can be explained, at least in part, by the association between APH and very preterm delivery.

The severity of maternal and neonatal outcomes is strongly influenced by the healthcare environment. Rapid access to blood products, emergency surgery, anesthesia, neonatal intensive care and specialist placental imaging can substantially alter prognosis. This is why regionalization of high-risk obstetric care is important. ACOG notes that outcomes for conditions such as placenta praevia and placenta accreta are improved when women are managed in hospitals with appropriate maternal care capabilities and experience.

4. Discussion

Pregnancy-related hemorrhage remains a clinical problem in which diagnostic accuracy and speed are equally important. The most important conceptual distinction emerging from the literature is that bleeding should not be regarded as a diagnosis in itself. It is a presenting symptom whose significance changes with gestational age and pregnancy anatomy.

In early pregnancy, the clinician's central task is to answer two questions: where is the pregnancy, and is it viable? These questions are deceptively simple because both may remain uncertain during the earliest stages of gestation. A positive pregnancy test accompanied by vaginal bleeding does not establish miscarriage, and the absence of an intrauterine gestational sac does not automatically establish ectopic pregnancy. The widespread availability of high-resolution ultrasound and serum hCG testing has improved diagnostic accuracy, but it has also introduced the risk of overdiagnosis when findings are interpreted without considering gestational age.

This is particularly relevant to early pregnancy loss. Modern ultrasound criteria have become deliberately conservative because the consequences of a false-positive diagnosis are irreversible. The current NICE approach requiring repeat scanning in uncertain cases and the emphasis of the 2025 Canadian guideline on avoiding incorrect diagnosis reflect a broader movement toward diagnostic safety.

At the same time, excessive caution can become harmful if it delays treatment of an ectopic pregnancy. The challenge is therefore to maintain diagnostic certainty without creating dangerous delays. Clinical instability, severe pain, significant hemoperitoneum or other evidence of rupture should override a prolonged diagnostic pathway. In these circumstances, the priority is resuscitation and definitive treatment.

The management of ectopic pregnancy has also become increasingly individualized. Surgical treatment remains essential for rupture and for patients with high-risk features, but expectant management and methotrexate allow selected stable patients to avoid surgery. The current NICE criteria provide a structured framework based on symptoms, ectopic size, fetal cardiac activity, serum hCG and ability to comply with follow-up.

The treatment of threatened miscarriage illustrates a similar shift toward selective intervention. Progesterone is now recommended by NICE for women with a confirmed intrauterine pregnancy who are bleeding and have previously miscarried. This is a more targeted strategy than the historical tendency to prescribe hormonal support broadly to women with early pregnancy bleeding.

APH presents a different clinical challenge because the pregnancy is generally advanced enough for fetal considerations to become central to decision-making. The clinician must constantly balance maternal safety against fetal maturity. In severe abruption, maternal instability or fetal compromise may necessitate immediate delivery even when the fetus is extremely premature. Conversely, stable patients with limited bleeding may sometimes be managed expectantly to allow further fetal maturation.

Placental abruption remains particularly difficult because there is no single diagnostic test with sufficient sensitivity to exclude the condition. The diagnosis is often clinical, and ultrasound is primarily useful for identifying alternative causes or occasionally demonstrating a hematoma. The clinician must therefore resist false reassurance from a normal scan.

Placenta praevia demonstrates the opposite problem: ultrasound is highly useful for diagnosis, and antenatal recognition can fundamentally change management. The major challenge is not merely identifying the placenta over the cervix but recognizing the potential coexistence of PAS. The rising incidence of caesarean delivery has increased the clinical importance of this relationship. RCOG's current placenta praevia/PAS guidance and ACOG recommendations both emphasize specialist imaging and planned delivery in appropriately resourced centers.

PAS is perhaps the clearest example of why modern obstetric hemorrhage management increasingly emphasizes prevention rather than rescue. Once a placenta accreta begins to separate uncontrollably, blood loss may become massive within minutes. By contrast, a diagnosis established before labor permits planned multidisciplinary delivery, blood-product preparation, anesthesia planning and surgical coordination. The difference between an anticipated hemorrhage and an unexpected hemorrhage can be clinically decisive.

Vasa praevia provides another illustration of the value of antenatal diagnosis. Because fetal blood loss rather than maternal blood loss is the primary danger, maternal vital signs can remain deceptively reassuring while the fetus rapidly becomes hypoxic. Antenatal identification followed by planned caesarean delivery has dramatically better outcomes than emergency recognition after membrane rupture.

One of the most important developments in the contemporary literature is therefore the movement from reactive to anticipatory obstetric care. Placental location should be documented; high-risk placentation should be recognized; previous caesarean delivery should prompt attention to PAS risk when the placenta is low; abnormal cord insertion and accessory placental lobes should raise awareness of vasa praevia; and women with significant APH should be assessed not only for the current bleeding episode but also for the likelihood of recurrence and preterm birth.

The role of multidisciplinary care cannot be overstated. Major obstetric hemorrhage is rarely managed successfully by one clinician working alone. Communication with anesthesia and transfusion services must occur early. Neonatal teams should be involved when preterm birth is possible. Women with suspected PAS should ideally be referred before a crisis develops. In health systems where specialist resources are limited, clear referral pathways and early transfer may be as important as any individual therapeutic intervention.

Another important consideration is health-system inequality. The outcome of APH depends not only on the underlying pathology but also on the time between onset of bleeding and access to definitive care. In settings with limited blood-bank capacity, delayed transportation or insufficient neonatal services, the same clinical condition may have dramatically different outcomes. The 2025 cohort study from Northern Ethiopia demonstrates the substantial maternal and perinatal burden associated with APH in a resource-limited environment.

Contemporary obstetric hemorrhage protocols should therefore be adapted to local realities. A protocol requiring immediate access to multiple blood components and specialist surgery is of limited practical value if those resources are unavailable. Conversely, resource limitations should not be used as a reason to abandon standardized recognition and stabilization. Basic measures—rapid identification of shock, intravenous access, blood sampling, early referral, fetal assessment and timely transfer—remain valuable in every setting.

The literature also demonstrates the importance of patient-centered care. Women experiencing miscarriage or ectopic pregnancy may simultaneously face physical pain, fear, grief and uncertainty about future fertility. Women with recurrent APH may experience anxiety every time they notice vaginal bleeding. A technically successful medical intervention can still be experienced as poor care if communication is inadequate.

Shared decision-making is particularly relevant when several management options are medically acceptable. This is evident in early pregnancy loss, selected ectopic pregnancy and some cases of stable APH. Women should be informed not only of the advantages of an intervention but also of the consequences of choosing expectant management or delaying delivery.

There are limitations to the current evidence base. Many recommendations concerning APH are based on observational data, expert consensus and retrospective cohorts because severe hemorrhage is difficult to study through randomized trials. Placental abruption is particularly difficult to investigate because no universal diagnostic standard exists. Studies often use different clinical definitions, which complicates comparisons across populations.

Similarly, evidence for conservative management of PAS remains less robust than evidence supporting planned caesarean hysterectomy. The rarity and severity of PAS make randomized trials difficult and ethically challenging. Future research will likely focus on improved imaging, biomarkers, fertility-preserving techniques and strategies for reducing blood loss.

Another limitation is that guidelines differ between countries. Definitions of APH, thresholds for intervention, use of Rh(D) immune globulin, criteria for methotrexate and timing of delivery may vary according to local policy, resources and interpretation of evidence. Therefore, this review should be understood as a synthesis of international evidence rather than a replacement for national clinical protocols.

Finally, the evidence surrounding obstetric hemorrhage continues to evolve. For example, recent research is examining prophylactic tranexamic acid in women with placenta praevia undergoing caesarean delivery. The 2026 phase 3 trial demonstrated a modest reduction in postpartum hemorrhage, but the intervention occurred after cord clamping and therefore does not establish tranexamic acid as routine treatment for antepartum bleeding itself.

The central clinical message remains straightforward despite the complexity of the subject: pregnancy-related bleeding should always be taken seriously, but it should not always be treated as catastrophic. The clinician's responsibility is to distinguish those two situations accurately. The best outcomes occur when dangerous bleeding is recognized early, unnecessary intervention in viable pregnancies is avoided, and high-risk placental conditions are identified before an emergency develops.

5. Conclusion

Hemorrhage during pregnancy encompasses a wide spectrum of disorders, from relatively benign first-trimester bleeding to life-threatening ectopic pregnancy, placental abruption, placenta praevia, placenta accreta spectrum and vasa praevia. Although early pregnancy bleeding and antepartum haemorrhage are clinically connected, they represent different diagnostic environments and should be approached according to gestational age and the anatomical and physiological circumstances of the pregnancy.

In early pregnancy, the principal objectives are to establish pregnancy location, determine viability and rapidly identify ectopic pregnancy. Transvaginal ultrasound and appropriately interpreted serial β-hCG measurements remain the foundation of diagnosis. Confirmed early pregnancy loss can be managed expectantly, medically or surgically according to clinical circumstances and patient preference. Current evidence supports selective use of vaginal micronized progesterone in women with early pregnancy bleeding and a previous miscarriage, while the diagnosis of pregnancy loss should be made cautiously to avoid interrupting a viable pregnancy.

In later pregnancy, APH requires a more immediate focus on maternal stabilization, fetal assessment and identification of placental pathology. Placental abruption remains predominantly a clinical diagnosis and may be concealed, while placenta praevia is usually identifiable by ultrasound and should prompt assessment for placenta accreta spectrum when risk factors are present. Vasa praevia is rare but particularly dangerous because fetal hemorrhage can progress rapidly after rupture of the membranes.

Modern management increasingly depends on anticipation rather than rescue. Antenatal identification of placenta praevia, PAS and vasa praevia permits planned delivery in appropriately equipped centers. For women with significant APH, access to blood products, anesthesia, emergency surgery and neonatal care can be lifesaving. The growing emphasis on multidisciplinary obstetric hemorrhage protocols reflects recognition that maternal and fetal outcomes are determined not only by the underlying pathology but also by the speed and organization of the clinical response.

Ultimately, the management of pregnancy-associated hemorrhage requires a balance between urgency and restraint. Urgency is essential when maternal or fetal life is threatened; restraint is equally important when diagnostic uncertainty exists and the pregnancy may still be viable. Contemporary evidence supports a patient-centered, multidisciplinary and risk-adapted approach in which diagnosis, stabilization, communication and definitive treatment proceed in parallel whenever possible. Continued improvement in maternal and perinatal outcomes will depend not only on new treatments but also on earlier recognition, better imaging, coordinated referral systems, reliable access to blood products and consistent implementation of evidence-based obstetric care.

References

1.     Royal College of Obstetricians and Gynaecologists. Antepartum Haemorrhage. Green-top Guideline No. 63. London: RCOG. The guideline defines APH as bleeding from or into the genital tract from 24+0 weeks until birth and reports an incidence of approximately 3–5% of pregnancies.

2.     National Institute for Health and Care Excellence. Ectopic pregnancy and miscarriage: diagnosis and initial management. NICE Guideline NG126. Updated June 2026.

3.     National Institute for Health and Care Excellence. Management of tubal ectopic pregnancy. NICE NG126. Updated June 2026.

4.     National Institute for Health and Care Excellence. Preterm labour and birth. NICE Guideline NG25. Current recommendations on antenatal corticosteroids, magnesium sulfate and tocolysis.

5.     American College of Obstetricians and Gynecologists. Early Pregnancy Loss. Practice Bulletin No. 200. Obstet Gynecol. 2018; current ACOG clinical guidance.

6.     Pymar H, Waddington A, Prager S, Shorter J, Thomas J. Guideline No. 460: Diagnosis and Management of Intrauterine Early Pregnancy Loss. J Obstet Gynaecol Can. 2025;47(Suppl 1):102914. doi:10.1016/j.jogc.2025.102914.

7.     Mehra VM, Farooqi S, Sriram P, Tunde-Byass M. Diagnosis and management of early pregnancy loss. CMAJ. 2024;196(34)–E1168. doi:10.1503/cmaj.231489.

8.     Expert Panel on GYN and OB Imaging; Laifer-Narin SL, Fruauff A, Cruz Romero C, et al. ACR Appropriateness Criteria® First Trimester Vaginal Bleeding: 2025 Update. J Am Coll Radiol. 2025;22(11S)–S538. doi:10.1016/j.jacr.2025.08.043.

9.     Long B, et al. Updates in emergency medicine: Ectopic pregnancy. Am J Emerg Med. 2024. doi:10.1016/j.ajem.2024.09.005.

10.  Schneider E, Kinzler WL. Placental Abruption: Pathophysiology, Diagnosis, and Management. Clin Obstet Gynecol. 2025;68(1):98–104. doi:10.1097/GRF.0000000000000903.

11.  Oyelese Y, Shainker SA. Placenta Previa. Clin Obstet Gynecol. 2025;68(1):86–92. doi:10.1097/GRF.0000000000000911.

12.  Royal College of Obstetricians and Gynaecologists. Placenta Praevia and Placenta Accreta: Diagnosis and Management. Green-top Guideline No. 27a. Fifth edition.

13.  American College of Obstetricians and Gynecologists. Placenta Accreta Spectrum. Obstetric Care Consensus No. 7. Obstet Gynecol. 2018;132–e275.

14.  Royal College of Obstetricians and Gynaecologists. Vasa Praevia: Diagnosis and Management. Green-top Guideline No. 27b. RCOG.

15.  Royal College of Obstetricians and Gynaecologists. Vasa Praevia: Diagnosis and Management. Green-top Guideline No. 27b. Peer Review Draft. 2026.

16.  Gebrekidan MG, Fisseha MA, Belay AG, Abreha GF. Effects of antepartum hemorrhage on maternal and perinatal adverse outcomes in Northern Ethiopia: a retrospective cohort study. BMC Pregnancy Childbirth. 2025;25:781.

17.  Independent risk factors for placental abruption: a systematic review and meta-analysis. PubMed-indexed systematic review and meta-analysis. 2025.

18.  American College of Obstetricians and Gynecologists. Rh D Immune Globulin Administration After Abortion or Pregnancy Loss at Less Than 12 Weeks of Gestation. Clinical Practice Update. 2025.

19.  American College of Obstetricians and Gynecologists. Prevention of Rh D Alloimmunization. Practice Bulletin No. 181. Obstet Gynecol. Reaffirmed 2026.

20.  World Health Organization. Consolidated guidelines for the prevention, diagnosis and treatment of postpartum haemorrhage. Geneva: WHO; 2025.

21.  World Health Organization. Consolidated guidelines for the prevention, diagnosis and treatment of postpartum haemorrhage: implementation guide. Geneva: WHO; 2026.

22.  World Health Organization. WHO recommendations on the assessment of postpartum blood loss and use of a treatment bundle for postpartum haemorrhage. Geneva: WHO; 2023.

23.  Zhang L, Bi S, Chen L, et al. Prophylactic tranexamic acid for the prevention of postpartum haemorrhage in women with placenta praevia: multicentre, double blind, randomised, placebo controlled, phase 3 trial. BMJ. 2026;393. doi:10.1136/bmj-2026-089636.

24.  American College of Obstetricians and Gynecologists. Levels of Maternal Care. Obstetric Care Consensus No. 9. 2019.

25.  Trostian B, McCloughen A, Shaban RZ, Curtis K. What assessment, intervention and diagnostics should women with early pregnancy bleeding receive in the emergency department and when? A scoping review and synthesis of evidence. Australas Emerg Care. 2025;28(1):1–11. doi:10.1016/j.auec.2024.09.006.